Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2162482 | 0.87 | CNR2 (0.52) | KMT2A | |
| SCHEMBL2162492 | 0.78 | NPC1 (0.42) | MAPTTP53KMT2AMEN1 | |
| SCHEMBL2162128 | 0.74 | CNR2 (0.44) | MAPTALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL2162358 | 0.73 | CNR2 (0.50) | MAPTGAAHPGD | |
| SCHEMBL2162159 | 0.72 | CNR2 (0.49) | MAPTLMNATP53ALDH1A1USP2 | |
| SCHEMBL2162421 | 0.71 | CNR2 (0.50) | MAPTGAAHPGD | |
| SCHEMBL2163174 | 0.70 | CNR1 (0.37) | MAPTLMNAALDH1A1GAAKMT2A | |
| SCHEMBL2162704 | 0.69 | MAPT (0.50) | MAPTLMNATP53ALDH1A1USP2 | |
| SCHEMBL4842211 | 0.68 | MEN1 (0.50) | MAPTLMNATP53ALDH1A1KMT2A | |
| SCHEMBL2163243 | 0.68 | CXCR2 (0.49) | MAPTLMNATP53ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985768-B2 | 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | claimed |
| WO-2008028094-A1 | COMPOUNDS AS CB2 CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | WO | claimed |
| US-20080058308-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | claimed |
| US-7985768-B2 | 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080058308-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058308-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | MAPT 1751/4885LMNA 4225/4885TP53 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.